http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2152676-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0647f1132fbc93524d7cb84f6135ed0a |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-368 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-78 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-689 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-37 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-573 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 |
| filingDate | 1994-01-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4962db4583fa4c4d12175062648e4532 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_06c17204bed41569b5240d89af24faa3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cd2df1a961f479a57039f19ed9dab7cd |
| publicationDate | 1994-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2152676-A1 |
| titleOfInvention | Assay method to rule out rupture of membranes in women at risk for imminent delivery |
| abstract | The present invention provides an assay that distinguishes those patients with imminent delivery with intact membranes from those in whom the membranes have ruptured. The method comprises obtaining a cervicovaginal secretion sample from a pregnant patient determined to be as at risk for imminent delivery by detection of a biochemical marker for imminent delivery in a cervicovaginal secretion sample from the patient and determining the level of IGFBP-1 in the sample. If the level of IGFBP-1 is elevated, the patient has rupture of membranes. If IGFBP-1 is not present, the patient has intact membranes. In a preferred embodiment, the method comprises obtaining a cericovaginal secretion sample from a pregnant patient after about week 20 of gestation and determining the level of fetal fibronectin and IGFBP-1 in the sample. The presence of an elevated fibronectin level in the sample indicates an increased risk of imminent delivery. If the level of IGFBP-l is elevated, the patient had rupture of membranes. If IGFBP-1 is not present, the patient has intact membranes. If IGFBP-I is not present, the IGFBP-I assay is preferably repeated. In those patients with an increased level of IGFBP-I, the test indicates that delivery cannot be delayed. |
| priorityDate | 1993-01-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 47.